THORNTON JOSEPH CLAY sold $110K of CLOV
THORNTON JOSEPH CLAY (Chief Financial Officer) sold 22,099 shares of CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV) at $4.97 ($0.11M total) on 2026-11-16.
CLOVER HEALTH INVESTMENTS, CORP. /DE
Clover Health offers Medicare Advantage insurance plans and technology-enabled care services for Medicare-eligible members, including people in underserved markets. Its plans include PPO and HMO products, with a wide physician network and options for members to see in-network and out-of-network primary care providers at the same cost-sharing. At January 1, 2026, Clover Health operated plans in five states and 203 counties. Its proprietary Clover Assistant platform provides physicians with patient data and personalized clinical insights to help identify and manage chronic diseases. Clover Health also runs clinical programs, including Clover Home Care, and markets the platform externally through subsidiary Counterpart Health as a software-as-a-service and technology-enabled services solution for payors and providers. The company earns money from its insurance business and contracts with providers to use Clover Assistant for a flat fee; its external platform offering is intended to provide additional revenue streams. Clover Health is a remote-first company and does not maintain a headquarters.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
THORNTON JOSEPH CLAY (Chief Financial Officer) sold 22,099 shares of CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV) at $4.97 ($0.11M total) on 2026-11-16.
CMS proposed reforms to combat fraud in Medicare, Medicaid, CHIP, and the Health Insurance Marketplace, aiming to save $90B over 10 years. The rule strengthens oversight, requires self-reporting of overpayments, and increases transparency. Managed care stocks fell, including UNH, HUM, CVS, CLOV, CNC, MOH, ELV, and OSCR. Medicare anti-fraud efforts saved $41.9B in 2025, with a $22.30 return per dollar spent.
CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV) filed an SEC Form 8-K — Regulation FD Disclosure. Clover Health (Nasdaq: CLOV) Third Quarter 2026 Supplemental Q&A November 16, 2026 Ahead of our third quarter 2026 earnings call, we invited shareholders to submit questions about Clover Health, our recent performance, and the outlook for our business. We appreciate the continued
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning CLOV (CLOVER HEALTH INVESTMENTS, CORP. /DE). Coverage has been balanced: 1 bullish, 0 neutral, and 1 bearish.
Recent CLOV coverage spans earnings, financial news and insider activity.
In the last 30 days, CLOV insiders filed 3 SEC Form 4 transactions — no purchases and 3 sales ($218K). The most active reporter was Reynoso Jamie L., CEO, Medicare Advantage, with 1 filing. 67% of those filings were made under pre-arranged Rule 10b5-1 plans.
Insider open-market sale may add mild negative sentiment, but it is not a fundamental catalyst by itself.
CMS’s fraud and enrollment oversight changes could increase compliance demands and affect Medicare Advantage risk adjustment outcomes.
The filing reinforces a path to improved Adjusted SG&A efficiency and continued AI investment, supporting the bull case for operating leverage but without new numeric guidance.
Earnings beat and upgraded outlook
Positive outlook may support the stock as investors anticipate earnings growth.
AlphAI scores every news story that mentions CLOV with an AI model for sentiment and relevance, and aggregates insider trades from CLOVER HEALTH INVESTMENTS, CORP. /DE's SEC EDGAR Form 4 filings. Figures refresh continuously.
THORNTON JOSEPH CLAY (Chief Financial Officer) sold 22,099 shares of CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV) at $4.97 ($0.11M total) on 2026-11-16.
CMS proposed reforms to combat fraud in Medicare, Medicaid, CHIP, and the Health Insurance Marketplace, aiming to save $90B over 10 years. The rule strengthens oversight, requires self-reporting of overpayments, and increases transparency. Managed care stocks fell, including UNH, HUM, CVS, CLOV, CNC, MOH, ELV, and OSCR. Medicare anti-fraud efforts saved $41.9B in 2025, with a $22.30 return per dollar spent.
CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV) filed an SEC Form 8-K — Regulation FD Disclosure. Clover Health (Nasdaq: CLOV) Third Quarter 2026 Supplemental Q&A November 16, 2026 Ahead of our third quarter 2026 earnings call, we invited shareholders to submit questions about Clover Health, our recent performance, and the outlook for our business. We appreciate the continued
Humana (HUM) reached a new 52-week high after reporting Q3 2026 earnings with a smaller loss and raised full-year EPS guidance. Competitors like CVS Health and Elevance Health also saw gains. Clover Health (CLOV) reported Q3 2026 earnings with a slight profit and raised full-year targets.
Clover Health (CLOV) expects growth in 2027 due to a rival's exit from New Jersey. The company anticipates higher enrollment and better medical loss ratios from members switching from other Medicare Advantage plans. Clover's five-star rating may boost year-round enrollment and direct sign-ups. The company plans to leverage its technology and evaluate new markets, with over $500 million in cash and no debt as of 2026.
Clover Health (CLOV) rose 9% in after-hours trading to $4.82, following a broader rally in managed care stocks. Humana's Q3 2026 earnings report drove sector gains, with Humana up 4.61% during regular trading. Clover's move outpaced peers like CVS Health and Elevance Health.
UBS kept its Neutral rating on Clover Health Investments but raised its price target to $5.50 from $5, a 10% increase. This implies a 22.8% upside from the Nov 5 close of $4.48, according to the firm.
Clover Health (CLOV) reported Q3 2026 earnings, highlighting 49% YoY membership growth to 157,000 members, 57% revenue increase to $2.3B, and doubled adjusted EBITDA to $97M. The company achieved high Star Ratings for its plans and improved HEDIS quality performance. Clover Assistant's engagement accelerated, driving better care and economics. The board appointed Clay Thornton as permanent CFO. Management expects continued growth and profitability in 2027 and 2028.
Clover Health (CLOV) filed an 8-K with the SEC, detailing corporate changes and voting matters. The filing includes exhibits and is available on the SEC's website. The specific details of the changes were not provided in the summary.
CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Clover Health Reports Third Quarter 2026 Results Business Highlights: • Strong third quarter performance brings year-to-date GAAP Net Income to $62 million alongside 49% year-over-year Medicare Advantage membership growth • Improved Full Year 2026 guidance across all